Investopedia
20 Aug 2026, 13:26 UTC · 21h ago
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Investopedia
20 Aug 2026, 13:26 UTC · 21h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Moderna and Merck announced that a Phase 3 trial of their experimental mRNA-based skin-cancer vaccine met its primary goal of recurrence-free survival. — Positive late-stage clinical trial results for a major disease indication typically drive massive valuation increases and future revenue expectations.
+0.90Moderna's shares rose 177% and Merck's rose approximately 12% following the trial announcement. — Immediate price action confirms strong market validation of the drug's potential and shifts investor sentiment for both companies.
+0.60The companies intend to share the trial data with regulators, though a specific timeline for submission was not provided. — While a necessary step for commercialization, the lack of a specific timeline introduces slight uncertainty regarding the time-to-market.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Shares soared 177% following positive Phase 3 trial data for a personalized skin-cancer vaccine.
Shares rose 12% due to positive late-stage trial results for its combination treatment with Moderna.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
23h ago
